The role of patient advocacy organisations in neuromuscular disease R&D – The case of the Dutch neuromuscular disease association VSN-Reference-Cited by-同舟云学术

The role of patient advocacy organisations in neuromuscular disease R&D – The case of the Dutch neuromuscular disease association VSN

Published:2010-02 Issue:2 Volume:20 Page:148-151
ISSN:0960-8966
Container-title:Neuromuscular Disorders
language:en
Short-container-title:Neuromuscular Disorders

Author:

Boon Wouter,Broekgaarden Ria

Publisher

Elsevier BV

Subject

Genetics (clinical),Neurology (clinical),Neurology,Pediatrics, Perinatology and Child Health

Reference19 articles.

1. Priority medicines for Europe and the World a “Public health approach to innovation”;Van Weely,2004

2. European Commission. Useful information on rare diseases from an EU perspective 2009. EU: Brussel; 2004.

3. EPPOSI. Report of the 7th EPPOSI workshop on partnering for rare diseases therapy development: positioning rare diseases on the healthcare agenda. Madrid, Spain; 2006.

4. WHO, Priority medicines for Europe and the World, World Health Organisation, Geneva; 2004, pp. 4–5.

5. RGO, Advies Orphan Drugs (weesgeneesmiddelen). 1998, Raad voor Gezondheidsonderzoek: Den Haag.

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Patient Organizations in Shaping Research, Health Policies, and Health Services for Rare Genetic Diseases: The Dutch Experience;Genes;2024-09-03

2. Population-based incidence rates of 15 neuromuscular disorders: a nationwide capture-recapture study in the Netherlands;Neuromuscular Disorders;2024-09

3. Patient engagement in preclinical laboratory research: A scoping review;EBioMedicine;2021-08

4. Incidence, Prevalence, and Geographical Clustering of Motor Neuron Disease in the Netherlands;Neurology;2021-01-20

5. Opportunities and barriers for innovation and entrepreneurship in orphan drug development;Technological Forecasting and Social Change;2020-12